Comparison of the survival implications of tumour-associated versus cancer-testis antigen expression in acute myeloid leukaemia.
Comparison of the survival implications of tumour-associated versus cancer-testis antigen expression in acute myeloid leukaemia.
We show that elevated levels of MGEA6 may be suggestive of improved survival for a subset of patients. In addition, we have shown, by RQ-PCR, that a distinct population of AML patients expressed elevated levels of the leukaemia-associated antigens G250 and/or PRAME and, by microarray, that the levels of expression of the AML TAAs described here were significantly different between patients and normal donors. The new data presented here and that of Greiner et al (2006) suggest that G250, PRAME and MGEA6 may act as biomarkers of good survival for a distinct population of AML patients. Better definition of the relevance of these 'distinctly high' TAA expressing patients may aid the future use of these markers in prognosis and MRD
tumour antigens, array, myeloid leukaemia, immunotherapy, acute leukaemia
510-512
Guinn, Barbara-Ann
728d28c9-a23d-413a-ba1d-4531005705d7
Tobal, Khalid
12607854-8ed3-4469-b18f-71db39547676
Mills, Ken I.
be9c4b93-fda3-40b1-8514-9191652ab8b7
Guinn, Barbara-Ann
728d28c9-a23d-413a-ba1d-4531005705d7
Tobal, Khalid
12607854-8ed3-4469-b18f-71db39547676
Mills, Ken I.
be9c4b93-fda3-40b1-8514-9191652ab8b7
Guinn, Barbara-Ann, Tobal, Khalid and Mills, Ken I.
(2007)
Comparison of the survival implications of tumour-associated versus cancer-testis antigen expression in acute myeloid leukaemia.
British Journal of Haematology, 136 (3), .
(doi:10.1111/j.1365-2141.2006.06454.x).
(Submitted)
Abstract
We show that elevated levels of MGEA6 may be suggestive of improved survival for a subset of patients. In addition, we have shown, by RQ-PCR, that a distinct population of AML patients expressed elevated levels of the leukaemia-associated antigens G250 and/or PRAME and, by microarray, that the levels of expression of the AML TAAs described here were significantly different between patients and normal donors. The new data presented here and that of Greiner et al (2006) suggest that G250, PRAME and MGEA6 may act as biomarkers of good survival for a distinct population of AML patients. Better definition of the relevance of these 'distinctly high' TAA expressing patients may aid the future use of these markers in prognosis and MRD
This record has no associated files available for download.
More information
Submitted date: February 2007
Keywords:
tumour antigens, array, myeloid leukaemia, immunotherapy, acute leukaemia
Identifiers
Local EPrints ID: 71570
URI: http://eprints.soton.ac.uk/id/eprint/71570
ISSN: 0007-1048
PURE UUID: 0aa28301-9459-4571-84e8-38d88d7a15e0
Catalogue record
Date deposited: 14 Dec 2009
Last modified: 13 Mar 2024 20:33
Export record
Altmetrics
Contributors
Author:
Barbara-Ann Guinn
Author:
Khalid Tobal
Author:
Ken I. Mills
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics